Log In
BCIQ
Print this Print this
 

NFC-1

  Manage Alerts
Collapse Summary General Information
Company Medgenics Inc.
DescriptionSmall molecule agonist of metabotropic glutamate receptor subtype 1 (mGluR1), mGluR3, mGluR5, mGluR7 and mGluR8
Molecular Target Metabotropic glutamate receptors (mGluR)
Mechanism of ActionMetabotropic glutamate receptor (mGluR) modulator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat ADHD in metabotropic glutamate receptor (mGluR)-positive patients; Treat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$483.0M

$2.0M

$481.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/09/2015

$483.0M

$2.0M

$481.0M

Get a free BioCentury trial today